

receptor 9 (TLR9) agonist, causes an additional, broad activation of the patient's immune system. Preclinical studies are ongoing in Germany. At BIO-Europe Spring 2009, 16-18 March 2009, Milan, Italy, Matthias Schroff, CEO of Mologen, and Arlett Killat, Business Development Associate, informed R&D Focus that MGN 1601 is available for partnering and/or licensing, worldwide. The company plans to start a phase I trial of MGN 1601 in second quarter 2009. MGN 1601 was granted Orphan drug status for the treatment of RCC in the EU in October 2006.

For further information on the partnering opportunities available, contact:

Arlett Killat
Business Development Associate
Mologen AG
Fabeckstr 30
14195 Berlin
Germany

Tel: +49 30 84 17 880
Fax: +49 30 84 17 88 50
Email: killat@mologen.com

Company Focus

Focus on AnaptysBio

Founded in 2005 and located in San Diego (USA), AnaptysBio uses somatic hypermutation (SHM) for antibody discovery and optimization. The company has a proprietary platform technology, designated SHM-Platform, which utilizes the key components of SHM to generate antibodies for therapeutic applications. In addition to advancing the SHM-Platform, AnaptysBio is developing an internal pipeline of therapeutic antibodies using this proprietary technology

SHM-Platform

AnaptysBio partnering opportunity, Worldwide

AnaptysBio's SHM-Platform technology utilizes key components of somatic hypermutation (SHM) to generate antibodies for therapeutic applications using an iterative process of natural evolution and high-throughput selection using flow cytometry. The SHM-Platform generates antibody

diversity in human-like manner, using a key enzyme called activation-induced cytidine deaminase (AID) which is responsible for antibody diversity generation in vivo. This approach has been referred to as "naturalizing" antibodies. The SHM-Platform can be used to discover novel antibodies and optimize existing antibodies directed at specific disease targets. By combining SHM with a novel mammalian cell display technology, AnaptysBio is able to evolve antibodies in an unconstrained manner without in vivo bias on antigen presentation. AnaptysBio has organized the SHM-Platform in a versatile, high-throughput manner such that antibody heavy and light chains can be simultaneously co-evolved and antibodies are rapidly selected to meet desired affinity, specificity, cross-reactivity, expression and stability parameters. AnaptysBio has also generated multiple fully human antibody libraries that are being utilized in conjunction with the SHM-Platform. These libraries are unencumbered with respect to target exclusivity provisions. Some aspects of the SHM-Platform were in-licensed by AnaptysBio from academic institutions, including the Medical Research Council (MRC;UK) and Albert Einstein College of Medicine (USA). Several patents covering the SHM-Platform have already been granted in USA and non-US jurisdictions, while numerous other applications are pending throughout the world. At BIO-Europe Spring 2009, 16-18 March 2009, Milan, Italy, William Boyle, President and Chief Science Officer at AnaptysBio, and Hamza Suria, Vice President, Corporate Development, informed R&D Focus that the company is open to partnerships with leading biopharmaceutical companies for affinity maturation of a partner's existing antibodies and/or de novo antibody discovery against disease targets of interest to the partner.

For further information on the partnering opportunities available, contact:

Hamza Suria
Vice President
Corporate Development
AnaptysBio
10835 Road to the Cure
Suite 100
San Diego
California 92121
USA

Tel: +1 858 362 6383
Fax: +1 858 366 9055
Email: hsuria@anaptysbio.com